Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319930 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
A Phase 1 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00319930 is a Phase 1 study that was terminated before completion, run by Biogen. The registered enrollment target is 10 participants.
The verdict
NCT00319930, a Phase 1 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.
Interventions
- DRUG CNF1010 (17-AAG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319930
The ClinicalTrials.gov registry entry for NCT00319930 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CNF1010 (17-AAG) is the first listed.
NCT00319930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00319930 about?
NCT00319930 is a clinical study titled "Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL". The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.
What is the current status of trial NCT00319930?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2005-05. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00319930?
The interventions under investigation include: CNF1010 (17-AAG) (DRUG).
Who is sponsoring clinical trial NCT00319930?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.